c-Met protein overexpression and telisotuzumab vedotin efficacy by biopsy age, type, and region in the LUMINOSITY phase II study

被引：0
|
作者：
Bar, J. [1 ]
Baijal, S. [2 ]
Luo, A. [3 ]
Zhang, N. [4 ]
Ratajczak, C. [5 ]
Ansell, P. J. [6 ]
Lu, S. [7 ]
Camidge, D. R. [8 ]
机构：
[1] Univ Hosp Birmingham, Sheba Med Ctr, Jusidman Canc Ctr, Ramat Gan, Israel
[2] NHS Fdn Trust, Med Oncol Dept, Birmingham, W Midlands, England
[3] AbbVie Inc, Oncol Stat, Chicago, IL USA
[4] AbbVie Inc, CDx Strategy & Precis Med, Chicago, IL USA
[5] AbbVie Inc, Oncol Early Dev, Chicago, IL USA
[6] AbbVie Inc, Precis Med Oncol, Chicago, IL USA
[7] Shanghai Chest Hosp, Shanghai Lung Canc Ctr, Shanghai, Peoples R China
[8] Univ Colorado, Med Oncol, Ctr Canc, Aurora, CO USA
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.08.1434
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1379P
引用
收藏
页码：S866 / S866
页数：1
相关论文
共 50 条
  • [1] Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein-Expressing Non-Small-Cell Lung Cancer
    Camidge, D. Ross
    Barlesi, Fabrice
    Goldman, Jonathan W.
    Morgensztern, Daniel
    Heist, Rebecca
    Vokes, Everett
    Spira, Alex
    Angevin, Eric
    Su, Wu-Chou
    Hong, David S.
    Strickler, John H.
    Motwani, Monica
    Dunbar, Martin
    Parikh, Apurvasena
    Noon, Elysa
    Blot, Vincent
    Wu, Jun
    Kelly, Karen
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (05) : 1105 - +
  • [2] Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein-Overexpressing Advanced Nonsquamous EGFR-Wildtype Non-Small Cell Lung Cancer in the Phase II LUMINOSITY Trial
    Camidge, D. Ross
    Bar, Jair
    Horinouchi, Hidehito
    Goldman, Jonathan
    Moiseenko, Fedor
    Filippova, Elena
    Cicin, Irfan
    Ciuleanu, Tudor
    Daaboul, Nathalie
    Liu, Chunling
    Bradbury, Penelope
    Moskovitz, Mor
    Katgi, Nuran
    Tomasini, Pascale
    Zer, Alona
    Girard, Nicolas
    Cuppens, Kristof
    Han, Ji-Youn
    Wu, Shang-Yin
    Baijal, Shobhit
    Mansfield, Aaron S.
    Kuo, Chih-Hsi
    Nishino, Kazumi
    Lee, Se-Hoon
    Planchard, David
    Baik, Christina
    Li, Martha
    Ansell, Peter
    Xia, Summer
    Bolotin, Ellen
    Looman, Jim
    Ratajczak, Christine
    Lu, Shun
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (25)
  • [3] Preliminary efficacy of telisotuzumab vedotin (Teliso-V) treatment in the 2L/3L setting in MET gene amplified ( MET Amp), c-Met protein overexpressing (c-Met OE), nonsquamous, non-small cell lung cancer (NSQ NSCLC): Retrospective analysis of LUMINOSITY
    Camidge, D. Ross
    Goldman, Jonathan
    Vasilopoulos, Athan
    Ansell, Peter
    Xia, Summer
    Bolotin, Ellen
    Looman, Jim
    Ratajczak, Christine
    Noon, Elysa
    Lu, Shun
    CANCER RESEARCH, 2023, 83 (08)
  • [4] Phase 2 Study of Telisotuzumab Vedotin (Teliso-V) in Previously Treated c-MET plus Non-Small Cell Lung Cancer: Trial in Progress
    Ocampo, C.
    Wu, J.
    Dey, J.
    Sun, Z.
    Motwani, M.
    Reddy, A.
    Parikh, A.
    Hay, J.
    Komarnitsky, P.
    Bach, B.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S646 - S646
  • [5] First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors
    Strickler, John H.
    Weekes, Colin D.
    Nemunaitis, John
    Ramanathan, Ramesh K.
    Heist, Rebecca S.
    Morgensztern, Daniel
    Angevin, Eric
    Bauer, Todd M.
    Yue, Huibin
    Motwani, Monica
    Parikh, Apurvasena
    Reilly, Edward B.
    Afar, Daniel
    Naumovski, Louie
    Kelly, Karen
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (33) : 3298 - +
  • [6] EGFR M plus Subgroup of Phase 1b Study of Telisotuzumab Vedotin (Teliso-V) Plus Erlotinib in c-Met plus Non-Small Cell Lung Cancer
    Camidge, D. R.
    Barlesi, F.
    Goldman, J.
    Morgensztern, D.
    Heist, R.
    Vokes, E.
    Spira, A.
    Angevin, E.
    Su, W.
    Hong, D.
    Strickler, J.
    Motwani, M.
    Sun, Z.
    Parikh, A.
    Komarnitsky, P.
    Wu, J.
    Kelly, K.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S305 - S306
  • [7] Telisotuzumab vedotin (Teliso-V) in combination with osimertinib in patients with advanced EGFR-mutated, c-met overexpressing, non-small cell lung cancer (NSCLC): Safety and efficacy results from phase Ib study
    Horinouchi, H.
    Goldman, J. W.
    Cho, B. C.
    Tomasini, P.
    Dunbar, M.
    Hoffman, D.
    Parikh, A.
    Blot, V.
    Camidge, D. R.
    ANNALS OF ONCOLOGY, 2022, 33 : S1592 - S1592
  • [8] A phase III global study of telisotuzumab vedotin versus docetaxel in previously treated patients with c-Met overexpressing, EGFR wildtype, locally advanced/metastatic nonsquamous NSCLC (TeliMET NSCLC-01)
    Lugini, A.
    Goldman, J. W.
    Tanizaki, J.
    Akamatsu, H.
    Xia, S.
    Ratajczak, C.
    Li, M.
    Bolotin, E.
    Seraj, J.
    Lu, S.
    ANNALS OF ONCOLOGY, 2023, 34
  • [9] Phase I Study of 2-or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, Monotherapy in Patients with Advanced Non-Small Cell Lung Carcinoma
    Camidge, D. Ross
    Morgensztern, Daniel
    Heist, Rebecca S.
    Barve, Minal
    Vokes, Everett
    Goldman, Jonathan W.
    Hong, David S.
    Bauer, Todd M.
    Strickler, John H.
    Angevin, Eric
    Motwani, Monica
    Parikh, Apurvasena
    Sun, Zhaowen
    Bach, Bruce Allen
    Wu, Jun
    Komarnitsky, Philip B.
    Kelly, Karen
    CLINICAL CANCER RESEARCH, 2021, 27 (21) : 5781 - 5792
  • [10] Phase Ib study of telisotuzumab vedotin (Teliso-V) and osimertinib in patients (Pts) with advanced EGFR-mutated (Mut), c-Met overexpressing (OE) non-small cell lung cancer (NSCLC): Final efficacy and safety updates
    Horinouchi, H.
    Cho, B. C.
    Camidge, D. R.
    Goto, K.
    Tomasini, P.
    Li, Y.
    Vasilopoulos, A.
    Brunsdon, P.
    Hoffman, D.
    Shi, W.
    Blot, V.
    Goldman, J. W.
    ANNALS OF ONCOLOGY, 2023, 34 : S1670 - S1670
12345